- Reuters
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2022 | Market Perform | Cowen | |
| 1/12/2022 | $6.50 | Reduce → Hold | HSBC Securities |
| 10/15/2021 | Market Perform | Cowen | |
| 9/27/2021 | $12.00 | Neutral → Underweight | JP Morgan |
| 8/31/2021 | $56.00 → $13.00 | Buy → Neutral | UBS |
| 8/4/2021 | $43.00 → $7.00 | Buy → Underperform | BofA Securities |
| 8/4/2021 | Outperform → Market Perform | Cowen & Co. | |
| 8/4/2021 | $55.00 → $12.00 | Buy → Neutral | Goldman Sachs |
15-12G - Zymergen Inc. (0001645842) (Filer)
EFFECT - Zymergen Inc. (0001645842) (Filer)
POS AM - Zymergen Inc. (0001645842) (Filer)
BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, and Zymergen (NASDAQ:ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome t
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac
EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability of operations for its existing platform. Octant has now more than doubled its initial investment through the purchase of an additional six RAC units, vastly increasing the system's throughput, capabilities, and ability to run complex workflows. "We've been extremely pleased with the performance of our current RAC System and are l
Cowen resumed coverage of Zymergen with a rating of Market Perform
HSBC Securities upgraded Zymergen from Reduce to Hold and set a new price target of $6.50
Cowen resumed coverage of Zymergen with a rating of Market Perform
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
4 - Zymergen Inc. (0001645842) (Issuer)
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the first quarter ended March 31, 2022. "Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process," said Zymergen's interim CEO, Jay Flatley. "We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation." Preliminary First Quarter 2022 Financial ResultsTotal r
EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. Investor Contactinvest
- Reuters
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares rose 17.5% to $4.10 in pre-market trading after the company said Q2 sales results were up year over year and raised FY22 sales guidance above estimates. Mainz Biomed B.V. (NASDAQ:MYNZ) rose 16.3% to $10.80 in pre-market trading. Mainz Biomed and Dante Genomics announced full commercial availability of ColoAlert in Italy and the United Arab Emirates. Treasure Global Inc. (NASDAQ:TGL) shares rose 12.8% to $8.12 in pre-market trading after the company reported closing of upsized $9.2 million initial public offering, Nasdaq listing, and full exercise of underwriter’s over-allotment option. Zymergen Inc. (NASDAQ:ZY) gained 12.2% to $3.49 in
SC 13G/A - Zymergen Inc. (0001645842) (Subject)
SC 13G - Zymergen Inc. (0001645842) (Subject)
SC 13G - Zymergen Inc. (0001645842) (Subject)